Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Multiple Myeloma (RRMM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT07102706
What this trial is testing

Phase I Trial of GR1803 Injection in Patients With RRMM

Who this might be right for
Multiple Myeloma (MM)
Genrix (Shanghai) Biopharmaceutical Co., Ltd. 76
Large-scale testing (Phase 3)Active Not RecruitingNCT06158841
What this trial is testing

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 421
Testing effectiveness (Phase 2)Active Not RecruitingNCT04790474
What this trial is testing

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple Myeloma
Tel-Aviv Sourasky Medical Center 61
Testing effectiveness (Phase 2)Ended earlyNCT04776018
What this trial is testing

TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda 27
Testing effectiveness (Phase 2)Ended earlyNCT06655818
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Who this might be right for
Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline 4
Large-scale testing (Phase 3)Active Not RecruitingNCT04975997
What this trial is testing

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene 939
Not applicableNo Longer AvailableNCT05462639
What this trial is testing

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer
Testing effectiveness (Phase 2)Study completedNCT06212596
What this trial is testing

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
University of Leeds 66
Early research (Phase 1)Not Yet RecruitingNCT07667868
What this trial is testing

A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)
BrightPath Biotherapeutics Co., Ltd. 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07695740
What this trial is testing

Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Excyte Biopharma Ltd 64
Early research (Phase 1)Looking for participantsNCT05759793
What this trial is testing

CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia
Nanjing IASO Biotechnology Co., Ltd. 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT07217184
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 30
Early research (Phase 1)WithdrawnNCT04998747
What this trial is testing

Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Amgen
Testing effectiveness (Phase 2)Looking for participantsNCT07455851
What this trial is testing

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 150
Not applicableStudy completedNCT05673967
What this trial is testing

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 62
Testing effectiveness (Phase 2)Temporarily pausedNCT06876142
What this trial is testing

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 54
Post-approval studies (Phase 4)Looking for participantsNCT07609940
What this trial is testing

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 30
Large-scale testing (Phase 3)Looking for participantsNCT07222761
What this trial is testing

Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 915
Testing effectiveness (Phase 2)Active Not RecruitingNCT02406222
What this trial is testing

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
University of Leeds 124
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06333509
What this trial is testing

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Who this might be right for
Multiple MyelomaPrimary Plasma Cell Leukemia
CARsgen Therapeutics Co., Ltd. 166
Next Page